Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
AMRS

AMRS - Amyris Inc Stock Price, Fair Value and News

0.01USD0.00 (0.00%)Market Closed

Market Summary

AMRS
USD0.010.00
Market Closed
0.00%

AMRS Stock Price

View Fullscreen

AMRS RSI Chart

AMRS Valuation

Market Cap

3.7M

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.01

EV/EBITDA

-1.14

Price/Free Cashflow

-0.01

AMRS Price/Sales (Trailing)

AMRS Profitability

Free Cashflow Yield

-12.5K%

AMRS Fundamentals

AMRS Revenue

AMRS Earnings

Breaking Down AMRS Revenue

Last 7 days

-75%

Last 30 days

-80%

Last 90 days

-98.9%

Trailing 12 Months

-99.6%

How does AMRS drawdown profile look like?

AMRS Financial Health

AMRS Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023268.2M000
2022222.7M235.6M258.8M269.8M
2021320.9M343.2M356.8M341.8M
2020167.3M134.6M133.9M173.1M
201960.1M107.8M128.4M152.6M
2018148.3M137.7M127.8M63.6M
201771.4M87.4M85.1M143.4M
201635.1M36.8M54.8M67.2M
201545.1M43.6M35.9M34.2M
201439.3M37.7M47.1M43.3M
201352.1M43.7M31.6M41.1M
2012139.3M126.5M109.4M73.7M
2011103.8M123.1M135.2M147.0M
2010069.8M75.1M80.3M
200900064.6M

Tracking the Latest Insider Buys and Sells of Amyris Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 07, 2024
mills steven richard
sold
-
-
-10,316
-
May 07, 2024
kieftenbeld hermanus
sold
-
-
-123,102
cfo and interim ceo
May 07, 2024
doerr l john
back to issuer
-
-
-87,268,400
-
May 07, 2024
dutra ana
sold
-
-
-10,950
-
May 07, 2024
mills steven richard
sold
-
-
-27,088
-
May 07, 2024
kung frank
sold
-
-
-6,796,200
-
May 07, 2024
doerr l john
back to issuer
-
-
-4,531
-
May 07, 2024
panchadsaram ryan
sold
-
-
-35,785
-
May 07, 2024
doerr l john
back to issuer
-
-
-46,047
-
May 07, 2024
doerr l john
back to issuer
-
-
-9,648
-

1–10 of 50

Which funds bought or sold AMRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 14, 2024
THURSTON, SPRINGER, MILLER, HERD & TITAK, INC.
new
-
23.00
23.00
-%
May 13, 2024
StepStone Group LP
sold off
-100
-7.00
-
-%
May 08, 2024
COZAD ASSET MANAGEMENT INC
unchanged
-
37.00
63.00
-%
May 08, 2024
FCA CORP /TX
unchanged
-
38.00
66.00
-%
Jan 09, 2024
IFP Advisors, Inc
sold off
-100
-36.00
-
-%
Nov 14, 2023
Ergoteles LLC
sold off
-100
-41,303
-
-%
Aug 11, 2023
Vident Investment Advisory, LLC
added
32.88
9,365
1,475,910
0.05%
Aug 10, 2023
PICTET ASSET MANAGEMENT SA
unchanged
-
-4,384
13,681
-%
Aug 09, 2023
Endurance Wealth Management, Inc.
unchanged
-
-17,000
34,000
-%
Aug 09, 2023
Veritable, L.P.
sold off
-100
-40,800
-
-%

1–10 of 24

Are Funds Buying or Selling AMRS?

Are funds buying AMRS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMRS
No. of Funds

Unveiling Amyris Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 07, 2024
foris ventures, llc
0.0%
0
SC 13D/A
Jan 05, 2024
foris ventures, llc
30.3%
122,898,614
SC 13D/A
Dec 14, 2023
foris ventures, llc
30.3%
122,726,324
SC 13D/A
Oct 16, 2023
foris ventures, llc
30.2%
122,255,166
SC 13D/A
Oct 05, 2023
foris ventures, llc
30.2%
122,178,837
SC 13D/A
Oct 02, 2023
foris ventures, llc
30.2%
122,140,768
SC 13D/A
Sep 20, 2023
foris ventures, llc
30.2%
122,034,555
SC 13D/A
Aug 10, 2023
foris ventures, llc
29.9%
120,499,897
SC 13D/A
Aug 03, 2023
foris ventures, llc
29.9%
120,480,436
SC 13D/A
Jun 30, 2023
foris ventures, llc
29.9%
120,385,914
SC 13D/A

Recent SEC filings of Amyris Inc

View All Filings
Date Filed Form Type Document
May 07, 2024
15-12G
15-12G
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading
May 07, 2024
4
Insider Trading

Peers (Alternatives to Amyris Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
57.2B
12.2B
12.87% -6.93%
23.16
4.71
-7.47% 13.44%
41.3B
43.5B
3.22% 14.01%
32.58
0.95
-18.61% -57.39%
17.0B
10.7B
0.39% 47.13%
8.54
1.59
7.11% 34.19%
17.0B
6.9B
1.54% 23.18%
65.26
2.47
-6.48% -57.90%
15.2B
8.4B
13.23% -37.88%
45.02
1.81
-4.27% -90.82%
11.8B
9.1B
3.76% 23.48%
12.72
1.29
-11.38% 33.67%
MID-CAP
5.6B
3.9B
9.59% 47.09%
12.57
1.44
-8.19% 39.97%
5.1B
929.6M
7.55% 27.14%
44.23
5.46
-1.74% 15.81%
4.2B
3.1B
9.31% 15.62%
39.66
1.33
-6.69% -83.56%
2.9B
3.0B
-3.97% 32.96%
9
0.98
-20.68% -74.38%
SMALL-CAP
1.2B
404.0M
0.11% 32.60%
36.59
3
24.06% -25.72%
665.6M
1.5B
-8.16% -27.13%
292.85
0.45
-21.27% -97.94%
183.9M
336.4M
2.92% 4.09%
10.09
0.55
-12.92% 28.47%
103.7M
16.7M
-5.80% -12.75%
-8.76
6.19
-57.58% -718.66%
3.7M
-
-80.00% -99.58%
-0.01
0.01
- -

Amyris Inc News

Latest updates
Yahoo News UK36 hours ago
Yahoo Singapore News09 May 202401:04 pm
InvestorPlace9 months ago

Amyris Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue-26.0%56,083,00075,802,00071,129,00065,207,00057,709,00064,776,00047,866,00052,316,000176,859,00079,744,00034,258,00030,005,00029,130,00040,536,00034,953,00062,694,00014,374,00016,371,00014,315,00015,059,00017,859,000
Costs and Expenses5.7%241,612,000228,626,000219,307,000208,628,000182,269,000193,634,000134,711,000107,185,00083,913,00082,723,00082,340,00070,566,00060,930,00072,416,00073,027,00065,205,00063,799,00065,032,00052,258,00041,657,00041,240,000
  S&GA Expenses-29.2%95,870,000135,417,000124,709,000126,587,000106,916,00094,914,00070,635,00054,340,00037,922,00036,233,00038,321,00030,503,00032,014,00034,130,00033,341,00030,862,00028,253,00026,109,00027,239,00019,454,00018,100,000
  R&D Expenses-7.6%26,765,00028,966,00028,780,00026,111,00026,358,00024,709,00023,824,00022,424,00023,332,00019,388,00018,197,00016,965,00017,126,00015,367,00019,032,00019,222,00017,839,00018,783,00016,445,00015,669,00017,825,000
EBITDA Margin-17.2%-2.18-1.86-1.21-0.78-0.26-0.70-1.08-1.08-1.49-1.54-1.51-1.96---------
Interest Expenses64.8%12,983,0007,877,0006,289,0005,304,0005,263,00010,748,0004,321,0004,723,0005,813,0006,204,0006,627,00020,118,00015,002,00042,948,00016,857,00015,217,00012,534,00013,965,0009,180,0009,580,0009,978,000
Income Taxes36.0%-860,000-1,344,000152,000-685,000-820,000-8,284,00058,00057,00055,00020,00083,00099,00091,00096,000533,000------
Earnings Before Taxes-33.3%-202,636,000-152,006,000-167,122,000-109,233,000-110,264,00035,517,000-34,084,00016,644,000-290,388,000-107,568,000-21,005,000-107,939,000-87,338,000-78,778,000-59,029,000-38,088,000-66,243,000-48,598,000-74,453,000-14,382,000-92,802,000
EBT Margin-17.9%-2.35-2.00-1.36-0.93-0.41-0.80-1.16-1.17-1.64-1.87-2.20-2.47---------
Net Income-36.0%-201,776,000-148,333,000-161,395,000-110,013,000-110,233,00037,845,000-32,944,00015,381,000-291,251,000-110,670,500-23,156,000-108,315,000-87,844,000-78,874,000-59,562,000-38,088,000-66,243,000-48,598,000-74,453,000-14,382,000-92,802,000
Net Income Margin-18.0%-2.32-1.96-1.33-0.91-0.40-0.79-1.18-1.19-1.66-1.91-2.23-2.49---------
Free Cashflow3.1%-90,001,000-92,877,000-133,534,000-147,041,000-152,442,000-142,170,000-69,368,000-78,446,000108,651,000-9,940,000-55,481,000-63,957,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Assets-17.6%680825754789898954542446327266206268167161128123105128123119118
  Current Assets-20.5%24430627231047163927834925214713119185.0074.0055.0046.0036.0092.0068.0067.0074.00
    Cash Equivalents-82.5%11.0064.0018.0010028848811521414430.0038.001003.002.002.001.005.0047.0019.0014.0024.00
  Inventory-2.6%10911212999.0082.0075.0072.0054.0048.0043.0037.0033.0031.0028.0016.0014.008.0010.006.007.005.00
  Net PPE4.1%19018217015112573.0053.0042.0032.0033.0030.0027.0027.0029.0024.0024.0022.0020.0017.0015.0013.00
  Goodwill-64.6%50.001431271341.001311294.00-------------
Liabilities2.7%1,3281,2931,1591,0331,024675596528637461285327343411336298337340323368404
  Current Liabilities21.6%47138730918726627046095.00147163104129192161159190236212154159111
  Long Term Debt0.1%67667567467367230912.0014.0014.00-25.0037.0046.0026.0063.000.0060.00-44.0044.0062.00
    LT Debt, Current2.7%2.002.002.001.001.001.0025.001.0056.0055.0031.0043.0077.0045.0065.0079.0012912462.0060.0034.00
    LT Debt, Non Current0.1%67667567467367230912.0014.0014.0026.0026.0024.0012.0048.0020.0010.0043.0043.0044.0044.0062.00
Shareholder's Equity------246------0.00--5.001.001,347---
  Retained Earnings-6.7%-3,073-2,880-2,730-2,568-2,458-2,357-2,395-2,362-2,377-2,086-1,977-1,953-1,843-1,755-1,676-1,617-1,579-1,521-1,367-1,298-1,300
  Additional Paid-In Capital0.4%2,4662,4562,3842,357-2,657---------------
Shares Outstanding1.0%369365325321313309287320268204189170---------
Minority Interest24.4%-9.76-12.91-13.10-6.60-3.52-0.752.006.006.005.004.003.001.001.001.001.001.001.001.001.001.00
Float----340---2,673---517---227-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Cashflow From Operations3.1%-90,001-92,877-133,534-147,041-152,442-142,170-69,368-78,446108,651-9,940-55,481-63,957-46,375-43,466-55,210-21,277-36,980-19,919-34,959-29,319-25,169
  Share Based Compensation-52.7%5,78512,22012,25612,64711,58811,4618,9058,7474,2813,8703,4382,9313,5042,4933,2343,3753,4523,0752,9371,9001,278
Cashflow From Investing-9.5%-4,815-4,399-30,086-41,936-47,286-23,517-34,911-3,177-2,493-3,162-4,125-4,454-1,040-4,067-3,062-2,905-3,046-6,110-1,998-2,780-1,584
Cashflow From Financing-70.9%41,614142,90681,2873,2623,958537,9084,816151,7097,5299,187-1,949165,62449,66346,16858,68820,276-22251,79741,38721,467-6,694
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AMRS Income Statement

2023-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:  
Revenue$ 56,083$ 57,709
Cost and operating expenses:  
Cost of products sold51,08148,995
Research and development26,76526,358
Sales, general and administrative95,870106,916
Change in fair value of acquisition-related contingent consideration(28,503)0
Restructuring1,0130
Impairment95,3860
Total cost and operating expenses241,612182,269
Loss from operations(185,529)(124,560)
Other income (expense):  
Interest expense(12,983)(5,263)
Gain from change in fair value of derivative instruments1,2631,815
(Loss) gain from change in fair value of debt(4,854)20,796
Other expense, net(533)(3,052)
Total other (expense) income, net(17,107)14,296
Loss before income taxes and loss from investment in affiliate(202,636)(110,264)
Benefit from income taxes860820
Loss from investment in affiliate0(789)
Net loss(201,776)(110,233)
Loss attributable to noncontrolling interest8,4342,928
Net loss attributable to Amyris, Inc. common stockholders$ (193,342)$ (107,305)
Earnings Per Share [Abstract]  
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.53)$ (0.34)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)365,603,738312,896,452
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.53)$ (0.37)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)365,603,738323,711,682
Renewable Products  
Revenue:  
Revenue$ 40,224$ 43,465
Licenses and Royalties  
Revenue:  
Revenue9,4829,313
Collaborations, Grants and Other  
Revenue:  
Revenue$ 6,377$ 4,931

AMRS Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 11,245$ 64,437
Restricted cash7171
Accounts receivable, net of allowance of $997 and $99536,84245,775
Accounts receivable - related party, net of allowance of $0 and $010,8366,608
Contract assets3,872806
Contract assets - related party33,67936,638
Inventories109,021111,880
Prepaid expenses and other current assets38,09540,146
Total current assets243,661306,361
Property, plant and equipment, net189,645182,224
Restricted cash, noncurrent6,1356,090
Recoverable taxes from Brazilian government entities30,18929,472
Right-of-use assets under financing leases, net147152
Right-of-use assets under operating leases, net100,72197,216
Goodwill50,456142,575
Intangible assets, net45,06346,938
Other assets13,66213,904
Total assets679,679824,932
Current liabilities:  
Accounts payable200,067190,486
Accrued and other current liabilities81,06873,565
Financing lease liabilities1413
Operating lease liabilities2,4842,255
Contract liabilities3326
Debt, current portion1,9681,916
Related party debt, current portion185,160118,886
Total current liabilities470,794387,147
Long-term debt, net of current portion675,855674,891
Related party debt, net of current portion77,96297,350
Financing lease liabilities, net of current portion4448
Operating lease liabilities, net of current portion90,98686,195
Derivative liabilities4,1405,403
Acquisition-related contingent consideration2,24134,555
Other noncurrent liabilities5,7257,053
Total liabilities1,327,7471,292,642
Commitments and contingencies
Mezzanine equity:  
Contingently redeemable common stock05,000
Contingently redeemable noncontrolling interest26,05828,892
Stockholders’ (deficit) equity:  
Common stock - $0.0001 par value, 550,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 368,524,240 and 364,745,266 shares issued and outstanding as of March 31, 2023 and December 31, 20223736
Additional paid-in capital2,465,8022,455,567
Accumulated other comprehensive loss(56,682)(64,114)
Accumulated deficit(3,073,520)(2,880,178)
Total Amyris, Inc. stockholders’ (deficit) equity(664,363)(488,689)
Noncontrolling interest(9,763)(12,913)
Total stockholders' (deficit) equity(674,126)(501,602)
Total liabilities, mezzanine equity and stockholders' (deficit) equity$ 679,679$ 824,932
AMRS
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
 CEO
 WEBSITEhttps://amyris.com
 INDUSTRYChemicals
 EMPLOYEES1598

Amyris Inc Frequently Asked Questions


What is the ticker symbol for Amyris Inc? What does AMRS stand for in stocks?

AMRS is the stock ticker symbol of Amyris Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amyris Inc (AMRS)?

As of Fri Oct 20 2023, market cap of Amyris Inc is 3.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMRS stock?

You can check AMRS's fair value in chart for subscribers.

What is the fair value of AMRS stock?

You can check AMRS's fair value in chart for subscribers. The fair value of Amyris Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amyris Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amyris Inc a good stock to buy?

The fair value guage provides a quick view whether AMRS is over valued or under valued. Whether Amyris Inc is cheap or expensive depends on the assumptions which impact Amyris Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMRS.

What is Amyris Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Oct 20 2023, AMRS's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMRS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amyris Inc's stock?

In the past 10 years, Amyris Inc has provided -0.561 (multiply by 100 for percentage) rate of return.